OPEN ACCESS: All - Des Spence, general practitioner, Glasgow
- destwo{at}yahoo.co.uk
GlaxoSmithKline has been fined $3bn (£1.9bn; €2.5bn)1—this follows other recent fines of drug companies: Merck,2 AstraZeneca,3 Johnson and Johnson,4 and Pfizer,5 reflecting a cultural problem across the industry, now allegedly all in the past. These fines come after decades of claims of manipulation of research, suppression of data, off-label promotion, excessive hospitality (gifts in all but name), expert panels paid bloated fees (educational mercenaries), withdrawal of dangerous drugs, disease mongering, payments made to advisory groups and charities, constant political …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
PDF
Social bookmarking